Meeting
2019 ASCO Annual Meeting
Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial.
Presenter
Robert Hugh Jones, MRCP, PhD
Velindre Cancer Centre and Cardiff University
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Clinical Trial Registration Number
NCT01992952
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1005)
DOI
10.1200/JCO.2019.37.15_suppl.1005
Abstract #
1005
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor–positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis.
Speaker: Robert Hugh Jones, PhD, FRCP
Speaker: Panel Discussion
Videos & Slides
2024 ASCO Annual Meeting
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
Speaker: Brad J. Stish, MD
Videos & Slides
2024 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.
Speaker: Alexander T. Pearson, MD, PhD